转移
唾液酸转移酶
基因沉默
癌症研究
乳腺癌
体内
RNA干扰
生物
转移性乳腺癌
癌症
半乳糖凝集素-3
抑制器
转移抑制因子
细胞
免疫学
核糖核酸
糖蛋白
分子生物学
基因
遗传学
作者
Nirupa Murugaesu,Marjan Iravani,Antoinette van Weverwijk,Aleksandar Ívetic,Damian A. Johnson,Aristotelis Antonopoulos,Antony Fearns,Mariam Jamal‐Hanjani,David Sims,Kerry Fenwick,Costas Mitsopoulos,Qiong Gao,Nick Orr,Marketa Zvelebil,Stuart M. Haslam,Anne Dell,Helen Yarwood,Christopher J. Lord,Alan Ashworth,Clare M. Isacke
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2014-02-12
卷期号:4 (3): 304-317
被引量:87
标识
DOI:10.1158/2159-8290.cd-13-0287
摘要
To interrogate the complex mechanisms involved in the later stages of cancer metastasis, we designed a functional in vivo RNA interference (RNAi) screen combined with next-generation sequencing. Using this approach, we identified the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor. Mechanistically, ST6GalNAc2 silencing alters the profile of O-glycans on the tumor cell surface, facilitating binding of the soluble lectin galectin-3. This then enhances tumor cell retention and emboli formation at metastatic sites leading to increased metastatic burden, events that can be completely blocked by galectin-3 inhibition. Critically, elevated ST6GALNAC2, but not galectin-3, expression in estrogen receptor-negative breast cancers significantly correlates with reduced frequency of metastatic events and improved survival. These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI